In the study titled “Safety of early postoperative hydrotherapy in dogs undergoing thoracolumbar hemilaminectomy”, the medical records of a single referral hospital in Sweden were retrospectively reviewed to identify dogs that had been treated with hemilaminectomy for acute or chronic thoracolumbar IVDE and had commenced hydrotherapy within five days after surgery.
Information collected from the medical records included signalment, presenting clinical signs, severity of neurological signs, initiation and duration of hydrotherapy, postoperative complications and follow-up.
Postoperative complications were considered major if there was a need for hospitalisation, surgery or if the dog died or was euthanised as a direct consequence of the complication.
A complication was deemed minor if outpatient medical treatment was sufficient to rectify it.
A total of 83 dogs were included in the study.
Hydrotherapy was started within a mean of 2.7 (one to five) days after surgery and consisted of swimming without underwater treadmill (UWTM) in dogs with severe paraparesis or paraplegia.
With neurological improvement, and when supported ambulation was possible, UWTM was initiated.
Ninety-six percent of the dogs used swimming as postoperative hydrotherapy, starting with a mean of 2.7 days after surgery, fifty-seven percent of the dogs used UWTM as the postoperative hydrotherapy, starting with a mean of 13 days after surgery.
Forty-five percent of dogs used both hydrotherapeutic modalities.
Dr Abtin Morjarradi, corresponding author for the paper, said: “A total of 10 minor complications were recorded during the study period, including surgical site infection (SSI) (n=5), diarrhoea (n=4) and urinary tract infection (n=1).
Major complications were recorded in 26 dogs during the study period and included euthanasia (n=13), acute dermatitis (n=1), spinal abscess (n=1) and disc extrusion (n=1).
Reasons for euthanasia were urinary incontinence (n=5), lack of neurological improvement (n=2), clinical suspicion of progressive myelomalacia (PMM) (n=2), persistent pain (n=1), aggression (n=1) and widespread cellulitis with an abscess caudal to the right stifle without known cause (n=1).”
Abtin added: “Follow-up visits for 71 dogs were performed at a mean of 15.3 (9 to 30) days, and 68 dogs at a mean of 45.9 (30 to 111) days, after surgery.
"At the first follow-up visit 68% of the dogs were ambulatory with Modified Frankel Score (MFS) 4 or higher.
"At the last follow-up visit 97% of the dogs were ambulatory with MFS 4 or higher, with 34% demonstrating normal neurological function. None of these dogs deteriorated after the initiation time of hydrotherapy.”
Nicola Di Girolamo, Editor of JSAP, said: “Whilst previous studies indicate that early rehabilitation may be beneficial after acute spinal cord injury, the optimal timing to start hydrotherapy is unclear.
“Despite a high number of complications being recorded in the present study, it is not clear how many of these complications were directly related to the initiation time of hydrotherapy and therefore further research is required.”
The full article can be found in the December issue of the Journal of Small Animal Practice: https://onlinelibrary.wiley.com/doi/full/10.1111/jsap.13412.
Reference
Current World Organisation for Animal Health (OIE) recommendations are to include a representative strain from each of the two sublineages of equine influenza virus (EIV) - Florida Clade 1 and Florida Clade 2, to deliver optimum protection.
MSD's study was designed to evaluate the efficacy of Equilis Prequenza, containing whole virus Newmarket/2/93 (European strain) and South Africa/4/03 (Clade1) EIV strains, and an HA canarypox vectored vaccine containing Florida Clade 1 and Clade 2 strains.
Two groups of seven Fjord ponies were vaccinated twice, 4 weeks apart (V1 on day 0 and V2 on day 28). One group was vaccinated with Equilis Prequenza (MSD AH) and one group with ProteqFlu (Boehringer Ingleheim). The protective antibody response was measured and ponies were challenged, along with six unvaccinated control ponies, by experimental infection with Wexford/14 (a heterologous clade 2 strain), 1 20 days (4.5 months) after V2, and clinical signs and virus shedding monitored. EI serology was measured by single radial haemolysis (SRH) and hemagglutination inhibition (HI). Clinical signs and virus shedding (measured by qRT-PCR and egg titration) were compared between groups and with controls.
Vicki Farr, BVetMed MRCVS, equine veterinary advisor at MSD Animal Health said: "Following challenge at 120 days after V2 with Wexford/14, this study demonstrates that both vaccines provide a highly significant degree of protection against clinical signs of EI and viral shedding compared to unvaccinated controls. Although the study was not designed to compare the efficacy of the two vaccines, because of practical limitations on the number of animals and hence low power, there was no evidence of any significant differences between these two groups. There was, however, a trend towards slightly lower clinical score on days 4-8 and reduced virus excretion on days 2-5 in the Equilis Prequenza group compared to the HA canarypox vectored vaccine.”
MSD says Equilis Prequenza offers a broad based approach to immunogenicity by addressing and adapting key areas of an equine influenza vaccine - Matrix-C adjuvant, whole virus antigen and strain; efficacy has been proven through challenge trials and longer term protection confirmed by serology.
Vicki added: "Equilis Prequenza addresses key factors involved in promoting effective immunogenicity. It combines the demonstrated efficacy against challenge, with a current circulating strain with an established safety profile. Equilis Prequenza stimulates active immunity against EI providing the reassurance your clients demand. MSD Animal Health is committed to working with equine practices to improve vaccination rates in at-risk horses."
For more information about the trial results contact your MSD Animal Health account manager.
Willows, the Solihull-based multidisciplinary referral centre, has announced that it has acquired The Veterinary Cardiorespiratory Centre, the renowned referral service run by Mike Martin MRCVS, RCVS Specialist in Veterinary Cardiology (pictured right).
Mike, together with Chris Linney and their team will shortly be moving half-an-hour up the road to join the team at Willows.
The company says that the move will offer a number of benefits to referring practitioners. Chief amongst these is the speed with which an accurate diagnosis can be made and treatment given, both as a result of having RCVS Specialists in neurology, imaging, medicine, soft tissue surgery (and now cardiology) under one roof and because of the state-of-the-art equipment at their disposal, including CT, MRI and digital fluoroscopy.
Lynne Hill, CEO, Willows Group said: ”I’m thrilled that Mike, Chris and their team are joining us at Willows. I have always held Mike in the highest regard and this is a tremendous opportunity for the practice to provide a truly collaborative ‘one-stop-shop’ for both clients and referring veterinary practices”.
Mike said: “I’m really looking forward to working at Willows Referral Service and being part of a multidisciplinary team. It's a logical move to provide Willows with the missing discipline of cardiology and I'm delighted Lynne Hill has allowed us to fulfil that role. There has been an increasing number of referrals between the two centres due to the complexity of cases - now that will be all under one roof and we can manage these much more effectively and offer the best service to our clients and their patients.”
For more information, visit www.willows.uk.net
There's a complimentary counter top unit and pillow packs to help veterinary surgeons and nurses communicate the benefits of probiotics to clients. The unit can hold a cat and dog 30 sachet box of Purina Pro Plan FortiFlora from practice stock and the pillow packs can be used to dispense single sachets, so the client can trial the product with their pet at home.
At the same time, the company is encouraging vets and nurses to look at the evidence behind the probiotics they recommend. Although carried out a while ago now (2003 and 2011), two studies have shown that other diets claiming to contain probiotics generally did not meet the label claim when evaluated1,2.
Libby Sheridan, MVB MRCVS, Purina Veterinary Technical Affairs Manager, UK & Ireland says the efficacy of probiotics is thought to be strain-specific3 and recommends that clinicians critically assess the evidence for the particular strain and preparation of probiotics stocked or used.
Libby said: "The quality and efficacy of probiotics can vary and while in some cases there is strong evidence for efficacy in the targeted species, for others, the evidence is scant. Having experienced it myself, I know it's not always easy when working in a busy practice to take the time to ensure the evidence is there, but the studies back up that we should assess these things carefully before making a robust recommendation to our clients."
Most of the probiotics commercially available to veterinary professionals use the lactic acid bacterium Enterococcus faecium.
The particular strain and preparation of any probiotic will affect its ability to reach the large intestine, the expected site of action, intact. The evidence for the SF68 strain of Enterococcus faecium has been validated in a number of studies4-11 over recent years. Proven benefits of the SF68 strain include those focused on the gastrointestinal system where it supports canine and feline intestinal health and microflora balance and those with wider implications, such as support for a healthy immune system.
To obtain a unit or discuss the science, contact your Purina Veterinary Nutrition Partner or telephone the Purina Veterinary Nutrition Team on 0800 212161 quoting code VETPRESS.
References
The webinars already available cover subjects like cardiopulmonary resuscitation (CPR), emergency diagnostics and traumatic brain injury, presented by experienced emergency vets Aoife Reid, Liron Levy-Hirsch and Jacqueline Seymour.
More content is due to be added to the library in the coming weeks, including guest webinars from TVM UK on rodenticide and seizure management, and from clinical psychologists Dr Jo Becket and Dr Jess Brown on “thrive, not just survive” and “when stress gets too much”. There will also be a session from ECC specialist Tobias Grave (pictured right) on how to deal with some of the most common pet emergencies.
Tobias will also be on hand to help veterinary surgeons and nurses whose practices use Vets Now for their out-of-hours service with both general advice and a second opinion on potentially complex cases via the new support line.
Tobias said: “Covid-19 is bringing fresh challenges to vets and vet nurses every day. With clinicians seeing a caseload which is mainly emergency and often having to triage patients over the phone or by video consult, it’s never been so important to come together as a profession.
"Both our webinars and our specialist support line for practices who use our service will help equip vet professionals with the skills and knowledge needed to deal with challenging emergencies in practice."
You can find Vets Now’s library of free ECC webinars here.
Bayer Animal Health has launched a next generation fluoroquinolone antimicrobial - Veraflox (pradofloxacin) - for the treatment of bacterial infections in cats and dogs.
Bayer Animal Health's marketing manager Dr Markus Edingloh said: "Veraflox, with its molecular compound pradofloxacin, developed exclusively for veterinary medicine, marks a major leap forward in veterinary antibiotic therapy and patient care.
"Veraflox has an enhanced spectrum of antimicrobial activity which encompasses Gram-positive and anaerobic bacteria. In addition, Veraflox has demonstrated high levels of bactericidal activity against target pathogens including activity against dormant bacteria typically found in chronic infections."
For cats, an oral suspension is available in which a fine-grained ion exchange agent binds to the antibiotic, apparently allowing it to pass the cat's taste buds undetected. Bayer says this innovation has been adopted specifically to ensure the product is palatable to cats, and help ensure owner compliance. The oral suspension comes with a syringe with both millilitre and gramme graduations, to help ensure accurate dosing.
Veraflox oral suspension is indicated for the treatment of upper respiratory tract infections, wound infections and abscesses. The 15mg tablet is also licensed in cats for treating upper respiratory tract infections.
Bayer says that in addition to its other indications, Veraflox is also very effective at combatting anaerobic bacteria that play a major role in aggressive bone destruction in canine periodontal disease, and it is the first fluoroquinolone to be licensed in dogs for the adjunctive treatment of severe infections of the gingiva and periodontal tissues.
In addition to its dental claim for dogs, Veraflox is also indicated for the treatment of wound infections, superficial and deep pyoderma, and acute urinary tract infections. It is given to dogs as a once-daily flavoured tablet.
Dr Edingloh added: "The unique chemistry and way in which Veraflox works gives it superior antibacterial activity compared with existing fluoroquinolones. In addition, during field studies, Veraflox was shown to be superior to other leading antibiotic products.
"Pradofloxacin has been proven to have a wide spectrum of activity, outstanding antibacterial activity, and an excellent safety margin. Its pharmacokinetic features ensure this active ingredient can rapidly get to the site of infection, at which it has a great impact on the pathogen population.
"One of the most common reasons for treatment failure where antibiotics are concerned is lack of owner compliance. The availability of Veraflox as an oral suspension with a graded syringe for cats, will enable more accurate dosing, far easier administration and so ensure higher cure rates.
"The launch of Veraflox is the first major advance in its class, since the introduction of Baytril, the first veterinary fluoroquinolone, over 20 years ago. Veraflox provides vets with more predictability, reliability and peace of mind, especially in difficult to treat infections."
For further information on Veraflox, please contact your Bayer representative or call 01635 563000.
The new Veterinary HPM Adult Neutered Wet with Salmon (a lifestage diet) and Urology Cat Wet (a clinical diet) have a high-protein low-carbohydrate formulation and a high share of animal protein.
Virbac points to studies which show that FLUTD is diagnosed in 8% of cats seen by vets for non-routine appointments1 and that there is a 51% risk of recurrence within one year of the initial diagnosis2.
Dr Rémi Mandray DMV MRCVS, Product Manager at Virbac, said: "Feline specialists recognise the importance of nutrition and water intake in the management of FLUTD, so we are delighted to be able to add two high quality wet diets to the Veterinary HPM range and therefore offer advanced nutritional solutions to such an important health issue."
Virbac says that both diets have high levels of animal protein to stimulate water intake, increase the volume of urine and stabilise the pH for a healthy urinary system.
The lifestage diets include supplements to limit phosphorus excretion in the urine for improved prevention of struvite crystal formation.
The company also says the Urology diets in the clinical range meet the PARNUT requirements for dissolution and prevention of struvite stones or crystals, and prevention of oxalate formation.
Virbac claims the new chunks in gravy wet diets naturally increase water intake by up to 50%, due to their high water content.
Dry and wets can be fed together as part of a mixed nutritional programme, to meet pet owner preferences identified in Virbac's market research: 60% of cat owners use wet food, mostly mixed with kibbles4.
For more information, contact your Virbac Territory Manager.
Bayer Animal Health has launched Tracer Advance Slim, a new, smaller microchip which is delivered through an implanter needle that - with a diameter of 2mm - is 20% smaller than its predecessor.
The company says that the new product will help vets and nurses reassure the 27% of owners that have said the size of the implanter needle caused them concern over whether they should get their animal chipped1.
Bayer also says slimmer microchips make microchipping more accessible for smaller species including exotic pets, birds and rabbits, which in turn means a potential new client base for vets.
Dan Calvo Carrasco MRCVS from Great Western Exotics, said: "The small size of the modern devices, combined with newer technology, increases the ease of implantation, causes less discomfort for the animal and makes microchipping suitable for almost any captive animal, including small birds, mammals and reptiles."
In addition, the new chip has a reading distance of up to 30cm, which Bayer says can help improve the welfare of those animals that are easily stressed, or difficult to handle.
Dan added: "Some animals do not tolerate handling well and longer reading distances will allow identification without the stress of catching and restraining the animals. Automated readers can be placed on tunnels, gates and nest areas, so microchips are read without handler intervention."
It's not just the owners of small species and exotics that have concerns about implanter needle size. First opinion equine vet Nathalie Cole said: "Whilst working as a first opinion practitioner I have met equine clients who have been concerned about the size of needle used and reported hearing stories of horses becoming very needle-shy following a microchipping experience. I can recall at least one client who gave needle size, perceived pain and stress to the horse as the reason for declining to have their horse chipped.
"Slimmer microchip products could be used to improve client perception and therefore uptake of microchipping, particularly given that the majority of UK equine microchip candidates are foals"
Bayer says that additional benefits of the new product include the fact that the transponder is encapsulated with an extremely robust bio-polymer which is ten times stronger than glass and less likely to shatter. Plus the new implanter has a removable needle which means sharps disposal should be easier and more cost-effective.
Tracer Advance Slim is available with a choice of registration options - online, postal or via participating Practice Management Software providers.
Tracer Advance Slim is available from veterinary wholesalers.
Andrew Parry MRCVS, an RCVS and European Specialist, heads Diagnostic Imaging at Willows. He said: "Our previous CT scanner was excellent but all technology moves on. We wanted to ensure we maintained our position at the forefront of specialist veterinary diagnostic imaging.
"We have a large cardiology service and the Siemens scanner, with its advanced cardiac imaging package, will allow the team to gain a huge amount of information about cardiac disease and other vascular abnormalities. This combination of technology and on-site Specialist imaging expertise is unusual, even at a referral level.
"A further advantage of the new scanner is its use of tin filters, which enables it to produce high quality images of regions of high contrast, such as feline chests."
Willows has also invested in a software package which does all sorts of clever stuff to bring the images to life for clients.
He said: “The syngo.via software allows anyone to access and manipulate images from any computer in the hospital. This can be building complex models or more straightforward multiplanar reconstruction.
"Specialists can show models to clients immediately, while surgeons can manipulate images in theatre and all clinicians can view and interact with images from their own working environment.
"Additionally, we have invested in Siemens-manufactured software called syngo.via Cinematic VRT, which means we can build, rotate and fly through volume rendered CT models with clients, giving them a dynamic understanding of anatomy and pathology."
The programme commences in October 2017 and includes ten days of hands-on practical training based at the CPD Solutions Training Centre in Studley near Birmingham, where surgery tutors will help veterinary surgeons refine their techniques in small group sessions.
CPD Solutions says the main differences with existing PgCert programmes include a stronger emphasis on practical training, a lack of lecture days and the grouping together of practical days in three attendance sessions.
The company says that many current PgCerts run for 2 to five years, so its programme provides an opportunity for those who'd prefer to complete their training and gain a PgCert qualification in a much shorter timeframe.
Susie Coughlan, MD at CPD Solutions said: "Our experience is that vets get the most out of hands-on practical training in a structured and supportive environment, combined with reflective application of their new skills in practice. We set out to replicate this with the new PgCert – all attendance sessions are practical, and the course provides support for developing reflective work-based learning that vets can then use throughout their careers."
David Perrin, Head of Professional Development at the Centre for Work-Related Studies at Chester University said: "The University is proud to be working with CPD Solutions as leading educationalists in the field of veterinary professional development. We have put together a high-quality product that brings together our work-based learning expertise with CPD Solutions specialist knowledge, and this will be of wide interest to practitioners in the field."
For more information, contact CPD Solutions on 0151 328 0444 or visit www.pgcertsurg.com
The Nu.Q Canine Cancer Test is a new technology that measures circulating nucleosomes in order to enable earlier cancer detection in some of the most common types of canine cancers.
According to the company, Nu.Q testing requires only 50µL of EDTA plasma from a patient and provides accurate results in 5 to 10 minutes.
One study demonstrated >75% detection rates for common cancers in dogs like lymphoma and hemangiosarcoma when using Nu.Q1.
The company suggests veterinary professionals use the tool during annual check-ups or regular senior wellness exams for older dogs and at-risk breeds.
Jimmy Barr, DVM, DACVECC, Chief Medical Officer at Antech, said: “It’s exciting to see innovations like Nu.Q Canine Cancer Test become more widely available to veterinary teams in Europe.
"With cancer affecting one in four dogs2, it is critical that veterinary professionals have access to fast and accurate cancer screening methods, so they can make informed and timely decisions and ultimately change pet health outcomes.
https://antechdiagnostics.co.uk
Merial Animal Health has launched Certifect, a new POM flea and tick treatment for dogs.
The product was launched at a series of presentations by the survival and bushcraft expert, Ray Mears (pictured right) last week.
The connection between Ray Mears and a new flea and tick treatment for domestic dogs became clear as he recounted his experience of contracting Lyme Disease in the UK. Indeed, by the time he'd finished describing the crippling pain he'd suffered and the industrial quantities of morphine and tramadol he'd needed, most vets in the room were probably ready to place an order for a tonne of the new product.
But to dismiss it as just a polished marketing exercise would be wrong. According to the Health Protection Agency, cases of Lyme disease in people have risen from 296 in 2001 to 953 in 2010. It is thought that because the disease is difficult to diagnose, it is likely to be significantly under-reported. In addition, a study by Faith Smith from the University of Bristol last year found that of 3534 dogs examined, 810 (22.9%) were carrying at least one tick.
So, what about the new product? Well, it's essentially Frontline Combo (fipronil + the insect growth regulator, S-methoprine) but with added amitraz. At the low dose contained in Certifect, Merial explained that amitraz doesn't demonstrate acaricidal properties itself, but instead potentiates the effect of the fipronil and causes ticks to detach or fail to attach. It also causes ticks to move around more than they do normally, thereby exposing them to more fipronil.
Merial says the acaricidal effect of Certifect can be seen two hours after application, and that more than 90% of ticks are eliminated within 24 hours. After treatment, Certifect prevented 94.5% to 100% of ticks attaching until day 29, thereby reducing the risk of disease transmission. In terms of integrated flea control, think Frontline Combo.
Certifect can be used on pregnant and lactating bitches, on puppies from 8 weeks weighing more than 2kg, and on dogs which live in households with cats.
Mark Naguib MRCVS, Public Relations Officer at the BVZS said: "Our conference is the largest gathering of exotic pet, wildlife and zoo vets in the UK and one of the best places to gain CPD in these fields whether you’re a new graduate or an experienced specialist."
The BVZS says it is subsidising the ticket price in recognition both of how the cost of living crisis is affecting the profession, and because after two years of socially-distanced online conferences, meeting in person is more important than ever.
The Society says it believes this is important enough that it is prepared to make a loss on the event in order to provide a real service not just to its members, but also to the whole veterinary zoological community.
The conference will once again feature dedicated streams covering zoo health, nursing, exotic pets and wildlife health.
There will also be a student stream, including back-to-basics exotics talks and a dedicated student networking session.
There will be evening entertainment on the Saturday and the opportunity to socialise and network.
https://www.bvzs.co.uk/bvzs/about/conference-2022
Elanco, a division of Eli Lilly and Company, has launched into the UK companion animal market with a pledge to listen to vets and provide a highly personalised level of support.
The company will initially offer recognised brands such as equine vaccines from the Duvaxyn range, Felocell vaccine for cats and equine wormer Strongid P. It says it is also developing a range of innovative new products designed to address the unmet needs of companion animals, the first of which are expected to be launched during 2011.
Mrs Tina Hunt, a Glasgow Vet School graduate and most recently, Veterinary Business Director at Fort Dodge UK, has been appointed with a remit to build the Elanco Companion Animal Health organisation in the UK. Reporting to Jannes Nijland, Director Elanco Western Europe, she will spearhead the company's growth and relationship building with veterinary practices across the country.
Tina said: "Recent changes in the animal health sector make it an exciting time to be launching a new companion animal brand. The opportunity to be in at the start and to shape a completely new business from scratch was too good to miss. My team shares a passion to combine the best of our experience with new approaches and new ways of working which are more closely attuned to what vets actually want. This means doing things differently and this is a challenge we relish.
We seek a genuine partnership with the profession and look forward to building close, individual relationships with vets and practices, helping them to enable companion animals to live longer, healthier and higher quality lives. While we're a newcomer in this sector, we benefit from the track record and resources available to Elanco, the fifth largest animal company in the world. We're determined to make Elanco Companion Animal Health a trusted and valued partner to vets working in companion animal practice."
Elanco develops and markets products to improve animal health and food-animal production in more than 75 countries. The company employs more than 2,300 people worldwide, with offices in more than 40 countries, and is a division of Eli Lilly and Company, a pharmaceutical corporation. Additional information about Elanco is available at www.elancopet.com and the company can be contacted via email: elancoCAH.uk@lilly.com
The long-awaited Panorama programme about the veterinary profession will air on Thursday 22 July at 9pm on BBC One.
Rumour has it that the programme will cover a range of issues, including the role of unqualified nursing staff in the practice, support for new graduates, over-charging in relation to insurance and regulation of corporate practices.
The RCVS says it expects increased public interest in the regulation of the profession following the programme and is gearing itself up to address any concerns it raises. A statement will be posted on www.rcvs.org.uk immediately following the programme, and the RCVS has said that it will work with the British Veterinary Association and other organisations to ensure that the robust nature of the regulatory system is communicated to the public, from undergraduate degrees through the Professional Development Phase and the Guide to Professional Conduct, to mandatory continuing professional development and the voluntary Practice Standards Scheme and Register for Veterinary Nurses.
In a statement issued today, the RCVS said: "We currently receive around 700 complaints a year - about one every 15 years of a member's practising life. It's a record to be proud of. However, if the programme raises areas of genuine concern, we will do all we can to act on them and we have already made it clear to the BBC that we would expect their support in this."
Genitrix has reformulated and repackaged its Lacto B range of broad spectrum probiotic supplements for the maintenance of normal digestive function in pets.
The products are provided in a powder formulation for direct application onto food or to be dissolved in water. They are available in five-day sachets or in 75g tubs suitable for longer term use.
Genitrix says that unlike single-strain formulations, the Lacto B range contains live freeze-dried cultures of three probiotic organisms which, when ingested, colonise the gut, helping to re-establish normal function. The three strains of probiotic organisms occupy the same sites in the gut as certain pathogenic bacteria thus preventing their attachment.
Indicated for dogs, cats, rabbits, rodents, reptiles and birds, the Lacto range is formulated to provide a guaranteed concentration of 1x109 CFU/g probiotic organisms.
Genitrix suggests that the Lacto B range can be particularly helpful in:
Rob Watkins, Marketing Director at Genitrix, said: "The Lacto range has been tried and trusted in small animal practice for twelve years and feedback shows that its multi-species indication make it a flexible and cost-effective solution."
"With its new formulation and new packaging, we believe it will prove even more attractive as a high potency probiotic supplement."
For more information, please click here.
Hosted on the Boehringer Academy website, the three-minute quiz involves listening to 15 murmurs and deciding whether each one is clinically significant or not.
After deciding, you'll be told the grade of the murmur and if further investigation should be considered to determine if the dog has cardiomegaly. Boehringer says this is important since dogs with MVD and cardiomegaly are more likely to develop heart failure within 1 to 2 years1.
To register on the Boehringer Academy or take part in the quiz, visit www.boehringer-academy.co.uk.
First you need to complete your VetSurgeon Profile, in particular the last four sections: "Qualified at", "Interests", "Interested in collaborating on" (aka goals) and "Memberships".
Then visit VetSurgeon Connect and click the button marked "Share My Location". This will activate the map beneath, allowing you to see local colleagues with common interests. It will also pin you on the map, but only in front of logged in members of the site with whom you have a common interest.
One area of common interest is the connection between general practitioners and referral practitioners. Referral practitioners who have shared their location are pinned on the map and can be seen by general practitioners (who can also filter them by discipline).
It is hoped that this will help create a more vibrant referral marketplace, as it offers referral practitioners who do not have big marketing budgets a way to connect with local general practitioners.
The system also matches VetSurgeon members by a number of other criteria. So for example, if you specify 'Qualified at' in your profile, it will display anyone else who went to the same vet school. If you display a leisure interest like cycling in your profile, it'll display other vets in your area who also like cycling.
If you display a clinical interest, such as oncology, it'll show you others in the area with the same interest.
The same thing happens with 'Interested in collaborating on', which connects you with others working towards the same goals, which can be business goals like practice ownership or a learning goals, such as CPD or being a mentor/mentee.
Lastly, if you specify your membership of a special interest veterinary association, the system will show you other members who are in your area.
VetSurgeon Editor Arlo Guthrie said: "It’s kind of a professional matchmaking service designed to make it easier than ever before for veterinary surgeons and others to hook up and collaborate on all sorts of different things.
"It may be you think you know everyone you need to know in your area already. But so often we think we know people, then find out we didn’t know about a shared passion for something, whether it be a professional or a leisure interest. Indeed, I think the system could be just as useful in connecting members to go on a bike ride together as it is to help them collaborate on CPD or on achieving additional qualifications."
Chris Taylor from Swann-Morton said: "We are really pleased to be part of this initiative which should help to bring the veterinary community closer together through shared experiences and knowledge."
Arlo added: "I’m very grateful for Swann Morton’s support. If you are too, you can show it by visiting the company's website and having a quick browse of the latest products in its veterinary range at www.swann-morton.com."
This multimillion pound centre will support the provision of advanced first opinion and referral equine services in the Midlands.
Senior Partner Richard Stephenson said: "It was a great honour and pleasure to have His Royal Highness visit our new premises, and our staff eagerly anticipated meeting Prince Charles and showing him the wonderful facilities we now have."
Amongst these are a Fujifilm SonoSite Edge II portable ultrasound system. Richard added: "Pool House is a well-known practice – we’ve been in existence for over 150 years – and we have developed a reputation as a specialist equine imaging centre, with radiography, ultrasound and MRI capabilities. The new facility has been designed to give us increased theatre capacity and stabling, and we needed an additional ultrasound system to match this expansion."
"The demands of equine practice mean that ultrasound is often required in difficult circumstances, and we need systems that can cope with extreme temperatures, dust, straw, mud, water and the occasional knock. Many pieces of equipment used in veterinary medicine were originally intended for a human clinical environment, so can’t stand up to the rigors of our work – they’re simply not fit for purpose. However, SonoSite systems are perfect for us; they’re robust, highly portable and very intuitive to use, which is important for intermittent ultrasound users."
Skin diseases and palpable masses are a common presentation in guinea pigs brought for veterinary care2.
However, few studies have thus far looked at the prevalence of spontaneously arising diseases in pet guinea pigs.
"Lumpy bumpy guinea pigs: a retrospective study of 619 biopsy samples of externally palpable masses submitted from pet guinea pigs for histopathology" retrospectively analysed 619 biopsy samples submitted for histopathology from pet guinea pigs that had presented with externally palpable masses.
The purpose was to determine the most common tissue origins of these masses and the most frequent pathological diagnoses, together with signalment data for the most commonly diagnosed lesions.
Of the 619 samples submitted from 493 animals, 54 (8.7%) had arisen from the mammary glands3 and 15 (2.4%) from the thyroid glands, with the remaining 550 (88.9%) involving the skin and subcutis, muscle (n = 1), salivary glands (n = 4), lips (n = 2), ears (n = 4) and peripheral lymph nodes (n = 23).
Forty-seven (7.6%) of the masses were diagnosed as inflammatory in nature, including dermatitis, panniculitis, lymphadenitis, cheilitis, myositis, sialoadenitis, abscess and chronic inflammation with osseous metaplasia.
Non-neoplastic, non-inflammatory lesions accounted for a further 31 (5.0%), namely cysts, hamartomas, hyperplastic lesions, polyps, ectopic bone formation and salivary gland steatosis.
The remainder of the samples were neoplastic in nature (541; 87.4%), with 99 masses classified as epithelial in origin, 347 as mesenchymal, 23 as round cell, five as melanocytic and eight as unclassified malignant neoplasms.
Of these, mesenchymal neoplasms were further subdivided into benign (288) and malignant (59).
Lipomas were the most common neoplasm diagnosed, accounting for 286 of all samples submitted.
Of all 619 samples included in the study, the eight most commonly diagnosed lesions were lipoma (46.2%), trichofolliculoma (12.3%), sarcoma (of various subtypes: 9.5%), inflammation (all sites 7.6%), lymphoma / leukaemia (3.4%), mammary carcinoma (4%), mammary adenoma (3.2%) and thyroid carcinoma (1.5%).
Overall these eight diagnoses accounted for 87.7% of all submissions from the externally palpable masses from the pet guinea pigs submitted for histopathology.
Melanie said: “Guinea pigs are an increasingly popular household pet.
"Skin diseases, including palpable masses, are a common reason for veterinary presentation. But few studies have been published to date that provide information for clinicians about these conditions.
“This study illustrates the importance of neoplasms of the skin and subcutis in pet guinea pigs, with over 87% of the cases analysed having one of eight diagnoses.
"While most of these neoplasms are benign, a substantial minority are malignant and identifying those lesions is especially important in treatment planning.
"Clinicians dealing with pet guinea pigs should also be aware that some externally palpable masses may arise from the thyroid or mammary glands rather than the skin or subcutis, and that male guinea pigs may also develop mammary lesions.”
The paper has been selected as ‘Editor’s Choice’ by the Journal of Comparative Pathology and will be free to access until September on Lumpy, bumpy guinea pigs: a retrospective study of 619 biopsy samples of externally palpable masses submitted from pet guinea pigs for histopathology - ScienceDirect.
Clomicalm contains Clomipramine hydrochloride, a broad-spectrum tricyclic antidepressant that inhibits the neuronal reuptake of serotonin and norepinephrine. A non-sedative, Clomicalm is used in combination with behavioural modification techniques to help separation anxiety.
Itrafungol is an oral solution containing Itraconazole for the treatment of ringworm in cats, administered orally directly into the mouth by means of a dosing syringe.
Both Clomicalm and Itrafungol are available to order from the veterinary wholesalers.
For more information, speak to your Virbac Territory Manager.
APPA is an oral, patented, fixed-dose combination of two synthetic secondary metabolites of plant origin, apocynin and paenol.
Under the terms of the agreement, AKL’s unnamed partner will fund a study in dogs with naturally occurring OA. The study will compare the efficacy and efficacy duration of APPA with the current standard of care for treating canine OA: non-steroidal anti-inflammatory drugs.
David Miles, AKLRD CEO, said: “Just like humans, millions of dogs suffer intolerable pain and disability because of OA and the current treatments just aren’t as effective or as well tolerated as they need to be. We already know from previous canine studies that APPA reduces pain and has an excellent tolerability profile but this exciting new partnership will allow us to go one stage further and assess sustainability of response.”
The randomised study will assess pain and duration of response as the primary endpoint. Secondary endpoint assessment will include adverse events, quality of life, pharmacokinetics analysis and biomarkers that may enable potential identification of factors predictive of response at treatment onset, or that correlate with response magnitude.
Two separate studies on dogs have already been carried out by researchers at the University of Vienna. The first, an 11-week cross-over study of 32 canines diagnosed with established, naturally occurring OA, showed that APPA provides significant symptom relief in clinical canine OA1.
A follow-up, five-week study of 60 dogs with OA compared APPA to the standard of care drug, meloxicam. It concluded that daily oral administration of APPA was effective as a stand-alone alternative to NSAIDs in dogs with naturally occurring OA. Significant benefits were also seen for APPA over meloxicam in orthopaedic examination as well as in lameness and function scores2.
The results will inform the pivotal clinical trial design and AKL says its working assumption is that a 26-week field study would complete the regulatory requirements for commercialisation.
If the study and future testing is successful, AKL estimates that APPA would be well placed to capture a significant share of the global canine OA market, which is estimated to be worth $3billion by 20283.
The new guidance is being launched as part of the company's Keeping Britain’s Pets Healthy (KBPH) preventative healthcare initiative.
The guidance includes 18 recommendations designed to help all members of the practice team to implement consistent, effective improvements in preventative healthcare.
The recommendations were the result of a package of research carried out by Dr Rachel Dean, Dr Marnie Brennan, Dr Natalie Robinson and Dr Zoe Belshaw at the university’s vet school, including a systematic review of the literature, a survey of veterinary surgeons and in-depth interviews with vets and owners. A final study used the Delphi technique to achieve consensus amongst 26 first opinion practitioners and 8 pet owners.
The recommendations invite practices to consider a number of ways they might improve the consultation process, including: the purpose of the consultation, the role of each member of the practice team, and how pet owner expectations should be addressed and communicated during the process.
John Helps, Senior Technical Manager at MSD Animal Health said: "Our new KBPH initiative marks a step change in our emphasis on preventative healthcare.
"It aims to champion the central role each member of the veterinary practice team plays as experts in educating and engaging our nation of pet lovers.
"These evidence-based guidelines are just the first step towards our increased emphasis on communicating the importance of the annual preventative health visit.
"They support the partnership between the practice and its clients around the health and welfare of their pets, and the significant contribution vaccines and parasiticides make to the health and welfare of their pets. They also help the whole team understand their specific role in the provision of preventative healthcare."
You can download the full recommendations here.
In the Somerset cull area, TB incidence has fallen from 24% before culling started to 12% in year four of the cull, while in Gloucestershire it has fallen from 10.4% to 5.6%.
The Government says the findings are in line with expectation based on the scientific evidence from the Randomised Badger Culling Trial which underpins the approach to tackling bovine TB – and demonstrate progress is being made in delivering the 25-year TB eradication strategy in England to rid our farmers of the impacts of this terrible disease.
Defra has also announced additional measures being taken to help control the disease, including licences for badger control in 11 new areas and the opening of a new round of applications for the Badger Edge Vaccination Scheme grants.
Farming Minister George Eustace said: "Bovine TB remains one of the greatest animal health threats to the UK. There is no single measure that will provide an easy answer which is why we are committed to pursuing a wide range of interventions to protect the future of our dairy and beef industries and eradicate the disease within 20 years.
"No one wants to be culling badgers forever so the progress reported today is encouraging."
BVA President John Fishwick said: "We continue to support a comprehensive and evidence-based approach to tackling bovine TB, including the use of badger culling in a targeted, effective and humane manner. TB is a devastating disease and we welcome the positive results emerging in Somerset and Gloucestershire, where licensed culling has now been in place for four years. The recent results in Dorset, indicating a slight upward trend in the incidence of bovine TB, present some cause for concern and we would like to see further investigation of the cattle and wildlife situation in that area.
"BVA supports the principle of badger controls within the Low Risk Areas (LRAs) of England where there is a demonstrated need and where it is done safely, humanely and effectively as part of a comprehensive strategy. We are largely reassured by the greater clarity provided on the decision-making process on how and where badger controls will be introduced in the LRAs. We recognise the expertise and professional judgement of veterinary and scientific colleagues in government who have made the decision to extend the cull in this area, but we would welcome further evidence regarding the level of TB infection in the wildlife reserve in Cumbria as this becomes available.
"Halting the spread of bovine TB is essential and it is vital that we use every available tool in the toolbox to support the Government’s aim to make England TB free. We therefore welcome both the introduction of tighter cattle controls where needed and the re-commencement of the Badger Edge Vaccination Scheme, particularly if used as a ‘firebreak’ to mitigate the spread of the disease into the low risk areas. We would also like to see a commitment to funding of further research in this area."
Photo: Coatesy/Shutterstock
Equibactin oral powder comes in a 60g sachet, which Dechra says is the scientifically considered accurate dose1 for two daily treatments for a 600kg horse. The sachets come in a box of 10, which is sufficient for the twice daily treatment of a 600kg horse for five days.
The combination of sulfadiazine and trimethoprim antibiotics (known as TMPS) has a broad spectrum of uses and can be used to treat equine infections associated with Streptococcus and Staphylococcus aureus, gastrointestinal infections associated with E. coli and urogenital infections associated with beta-hemolytic streptococci.
Emma Jennings, Equine and Food Producing Animal Brand Manager, said: “Our product allows for twice daily 30mg/kg treatments, making the treatment of large horses easier and ensuring they receive the correct dose, which is crucial when it comes to tackling antibiotic resistance.”
She added: “TMPS is the only registered oral antibiotic available for use in horses and it is recommended as the first line of treatment for ‘common’ equine bacterial infections including those which have developed through wound infections or open or drained abscesses.2,3
“Effective antibiotics are an important part of the veterinarian’s arsenal when it comes to treating a variety of common bacterial infections in horses. But in recent years, the emergence of drug resistant bacteria has meant that extra precautions must be taken to prevent underdosing - one of the prominent causes of drug resistance.”
Equibactin oral powder is available now in the UK and Ireland. For more information visit www.dechra.co.uk.